Marker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T Relapse

December 15, 2023

https://www.globenewswire.com/news-release/2023/12/11/2793733/0/en/Marker-Therapeutics-Announces-Sustained-Complete-Response-in-First-Lymphoma-Patient-Treated-with-MT-601-following-CAR-T-Relapse.html

HOUSTON, Dec. 11, 2023 (GLOBE NEWSWIRE) — Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today reported a clinical update on the APOLLO study. The Phase 1 APOLLO study is investigating MT-601, a multi-tumor associated antigen (multiTAA)-specific T cell product, for the treatment of patients with lymphoma who have failed or are ineligible to receive anti-CD19 CAR T cell therapy.

Read more at globenewswire.com

Related news for (MRKR)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.